January 15th 2025
Building on a previous report that revealed corrupt business practices among the big 3 PBMs, a second interim report finds that PBMs heightened prices for important specialty generic drugs to increase their profit margins.
Specialty Drug Copay Coupons: Despite Patient Benefits, Compliance Issues Persist
June 2nd 2016Conflicting opinions surround drug copay coupons, which can improve out-of-pocket costs while decreasing the effectiveness of cost-sharing requirements that promote prudent prescribing and purchasing choices.
Navigating the Complexities of Pharmacy Reimbursement: Will We Ever Reach Transparency?
March 23rd 2016Evolution in the pharmacy reimbursement system represents a crucial component toward stabilizing costs and providing fair margins for pharmacy sustainability, particularly in rural and underserved areas.